Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

Gniadecki, Robert; Kragballe, Knud; Dam, Tomas Norman; Skov, Lone

doi:10.1111/j.1365-2133.2011.10213.x

Cited by 238 publications

(315 citation statements)

References 19 publications

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…Successes achieved with currently available agents have raised the bar such that the goal for treatment is as low a state of disease activity as possible for all patients. Because conventional DMARD and biologic agents are not effective or tolerated in all patients, additional therapies are indicated 8,9,10,11,12,13 . Based on shorter-term data, apremilast showed the potential to offer patients with active PsA an additional treatment option.…”

Section: Discussionmentioning

confidence: 99%

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

Mease²,

et al. 2015

View full text Add to dashboard Cite

Objective.To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, over 52 weeks in patients with active psoriatic arthritis (PsA) despite prior treatment.Methods.Patients were randomized to placebo (n = 168), apremilast 20 mg BID (n = 168), or apremilast 30 mg BID (n = 168). Patients whose swollen and tender joint counts had not improved by ≥ 20% at Week 16 were considered nonresponders and were required to be re-randomized (1:1) to apremilast 20 mg BID or 30 mg BID if they were initially randomized to placebo, or continued their initial treatment of apremilast dose. At Week 24, all remaining patients treated with placebo were re-randomized to apremilast 20 mg BID or 30 mg BID.Results.An American College of Rheumatology 20 (ACR20) response at Week 16 was attained by significantly more patients receiving apremilast 20 mg BID (30.4%, p = 0.0166) or 30 mg BID (38.1%, p = 0.0001) than placebo (19.0%). Among patients receiving apremilast continuously for 52 weeks (n = 254), ACR20 response at Week 52 was observed in 63.0% (75/119, 20 mg BID) and 54.6% (71/130, 30 mg BID) of patients. Response was also maintained across secondary outcomes, including measures of PsA signs and symptoms, skin psoriasis severity, and physical function. The nature, incidence, and severity of adverse events were comparable over the 24-week and 52-week periods. The most common adverse events, diarrhea and nausea, generally occurred early and were self-limited.Conclusion.Continuous apremilast treatment resulted in sustained improvements in PsA for up to 52 weeks. Apremilast had an acceptable safety profile and was generally well tolerated. Clinical trial registration: NCT01172938.

show abstract

Section: Discussionmentioning

confidence: 99%

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

Mease²,

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Previously reported data demonstrated that adalimumab, a biological drug, is an efficacious treatment for psoriatic arthritis and rheumatoid arthritis and is FDA approved for psoriasis. Adalimumab is a fully human monoclonal antibody IgG I against tumor necrosis factor alpha, which is able to interfere with the TNF-alpha activities (8)(9)(10). We sought to characterize the pattern of innate immune receptors in psoriatic skin of patients treated or not with adalimumab, in particular TLRI and TLR2, mostly involved in psoriasis, to clarify their role and to gain further insight into the potential role of such components for new therapeutic approaches.…”

Section: Fig 2 Immunohistochemical Staining Oftlr2 In a Healthy Patmentioning

confidence: 99%

Modulation of Toll-like Receptors in Psoriatic Patients during Therapy with Adalimumab

Pità

Nardis

Lupi

et al. 2011

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Toll-like receptors (TLRs) are a key part of the innate immune system that detect pathogenassociated molecular patterns (PAMPs) of microorganisms and their stimulation results in the activation of signaling pathways leading to the modulation of inflammatory and immune responses. Since psoriasis is a complex, inflammatory and immune skin disease, characterized by an abnormal immune response and increased proliferation of keratinocytes, with an increased production of proinflammatory cytokines, TLRs could play an important role in the pathogenesis of the disease. We propose to assess the modulation of TLR expression on psoriatic skin of patients treated with Adalimumab and systemic conventional therapies. We therefore recruited fifteen patients: ten were treated with adalimumab and five with systemic conventional therapies; their clinical conditions were analyzed by PASI index and skin biopsies were evaluated for TLRI and TLRl expression by immunohistochemistry assays. Our data suggest adalimumab is not only able to improve the clinical condition of psoriatic patients, but also to modulate TLRI and TLRl expression involved in psoriasis, as in healthy skin. Adalimumab is a most promising biological drug able to orchestrate immune and inflammatory responses in psoriatic lesions, recovering TLR expression on basal keratinocytes and improving clinical conditions of psoriatic patients, with no evident side effects.

show abstract

“…One study compared drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. The drug survival rates were most favourable for infliximab, followed by adalimumab and etanercept [63].…”

Section: Discussionmentioning

confidence: 98%

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

Janknegt¹

2016

J Pharma Care Health Sys

View full text Add to dashboard Cite

The treatment of plaque psoriasis is changing because of the introduction of new treatment options. The goal of this article is to allow a transparent and rational choice of medicines by means of the System of Objectified Judgement Analysis. The following selection criteria (relative weight) were applied: approved indications (40), drug interactions (60), clinical efficacy (400), safety (300), dosage frequency (100) and documentation (100). Acquisition cost was not taken into consideration to allow a preselection on quality aspects only. Adalimumab, etanercept, infliximab and ustekinumab were compared on these criteria. Infliximab and ustekinumab showed the highest scores and are the most suitable medicines for the treatment of severe plaque psoriasis. Of course, cost will play a key role in the final selection in individual hospitals. Weight Approved indications 40 Drug Interactions 60Clinical efficacy 400Safety 300Dosage frequency 100 Documentation 100Total 1000 Selection Criteria Approved IndicationsThe number of licensed indications is a good measure of the applicability and documentation of the drugs. Although this analysis is limited to the treatment of plaque psoriasis, the fact that a drug is approved for (almost) all indications listed below is, from a formulary point of view, advantageous to another drug, which is approved for only one or two applications.The percentage of the maximum score for approved indications was obtained as follows (Table 2): IndicationMaximum Score (%)Plaque psoriasis 50% Psoriatric arthritis 20%Rheumatoid arthritis 10% Spondylitis ankylopoetica 10%Inflammatory bowel disease 10% Drug interactionsInteractions play a role only in patients who use other drugs which may interact with biologicals. However, it is a relevant criterion from a formulary point of view.The score for each drug was dependent on the frequency and severity of observed drug interactions. Clinical efficacyClinical efficacy is always a very important selection criterion for any group of drugs. The score for each drug was derived from the results of double-blind comparative studies. SafetyThe extent and the severity of adverse effects is another important selection criterion for drugs. A distinction was made between "minor" side effects, such as gastrointestinal disturbances or skin reactions, occurring in clinical trials and severe or even life-threatening adverse reactions observed with large scale use of the drugs. The evaluation of the "minor" adverse effects was based on results of double blind comparative clinical studies.

show abstract

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

Cited by 238 publications

References 19 publications

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

Modulation of Toll-like Receptors in Psoriatic Patients during Therapy with Adalimumab

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

Contact Info

Product

Resources

About